Ole Andreas Halvorsen
Viking Global Investors
Ole Andreas Halvorsen Tenet Healthcare Corp stake
total: 670
Viking Global Investors THC trades
- Total transactions:
- 11
- New positions:
- 3
- Sold out:
- 3
- Added:
- 3
- Reduced:
- 2
- Held since:
- 2023 Q2
- Held for:
- 2 quarters
- Latest activity:
- 2023 Q4
According to 2026 Q2 report, Ole Andreas Halvorsen doesn't hold any Tenet Healthcare Corp (THC) shares. To date, the estimated cost basis is nearly $71.38 for "buy" trades and estimated average "sell" price is $65.89. Viking Global Investors first purchased THC in 2021 Q1, initially acquiring about 1.46M shares. Ole Andreas Halvorsen later completely sold out the position and invested in Tenet Healthcare Corp again in 2023 Q2. Since the initial investment in Tenet Healthcare Corp (THC), Viking Global Investors has made 10 more transactions.
When did Ole Andreas Halvorsen sell Tenet Healthcare Corp (THC)?
Ole Andreas Halvorsen sold off the entire Tenet Healthcare Corp (THC) position in 2023 Q4.
When did Ole Andreas Halvorsen buy Tenet Healthcare Corp (THC)?
Ole Andreas Halvorsen first invested in Tenet Healthcare Corp (THC) in 2021 Q1 at the reported quarter-end price of $52.00 per share.
What's the cost basis of Viking Global Investors's THC stake?
The estimated cost basis for Tenet Healthcare Corp (THC) stake is around $71.38 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $71.38
- Weighted AVG sell price:
- $65.89
Ole Andreas Halvorsen's historical trades in Tenet Healthcare Corp
11 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q4
|
0.00%
|
0
|
$65.89
|
|
-100% (-1,025,840)
|
-0.27%
|
|
2023 Q3
|
0.27%
|
1,025,840
|
$65.89
|
$67,592,598
|
+181.98% (+662,040)
|
+0.18%
|
|
2023 Q2
|
0.12%
|
363,800
|
$81.38
|
$29,606,044
|
new
|
+0.12%
|
|
2022 Q4
|
0.00%
|
0
|
$51.58
|
|
-100% (-383,510)
|
-0.09%
|
|
2022 Q3
|
0.09%
|
383,510
|
$51.58
|
$19,781,000
|
new
|
+0.09%
|
|
2022 Q2
|
0.00%
|
0
|
$85.96
|
|
-100% (-2,233,647)
|
-0.78%
|
|
2022 Q1
|
0.78%
|
2,233,647
|
$85.96
|
$192,004,000
|
-30.44% (-977,594)
|
-0.24%
|
|
2021 Q4
|
0.76%
|
3,211,241
|
$81.69
|
$262,326,000
|
-4.25% (-142,615)
|
-0.03%
|
|
2021 Q3
|
0.61%
|
3,353,856
|
$66.44
|
$222,830,000
|
+47.15% (+1,074,674)
|
+0.2%
|
|
2021 Q2
|
0.46%
|
2,279,182
|
$66.99
|
$152,682,000
|
+55.97% (+817,869)
|
+0.17%
|
|
2021 Q1
|
0.23%
|
$52.00
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.